Abiopharma

🔍 Lee Sung (Executive)

Company: Tango Therapeutics, Inc. (TNGX)

Report Date: 2026-04-29

Detailed Transactions and Holdings:

• Acquired 12,300 shares of Common Stock (Direct)
  Date: 2026-04-29 | Code: A | equity_swap_involved: false | shares_owned_after: 22,300.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 5,200 shares of Stock Option (Right to Buy) at $22.06 per share (Derivative)
  Date: 2026-04-29 | Code: A | Expires: 2036-04-29 | equity_swap_involved: false | shares_owned_after: 5,200.00 | transaction_form_type: 4 | Footnotes: F2

Footnotes:

• F1: These shares are represented by restricted stock units (the "RSUs"). Each RSU represents a contingent right to receive one share of Common Stock of the Issuer. The RSUs will vest in three substantially equal annual installments on January 2, 2027, January 2, 2028 and January 2, 2029, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The RSUs were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy.
• F2: This option shall vest and become exercisable in 36 substantially equal monthly installments over a period of three years commencing on January 2, 2026, subject to the Reporting Person's continuous service with the Issuer as of each such vesting date. The options were granted in connection with the Reporting Person's service on the Issuer's board of directors and reflect the value the Reporting Person is entitled to pursuant to the Issuer's Non-Employee Director Compensation Policy.